MAPT and Alzheimer disease: Predicting amyloid and tau biomarkers from MRI to identify individuals at risk for AD represents a surrogate modeling strategy or a proxy‐marker learning approach that aims to capture the core pathological indicators of AD, rather than focusing solely on clinical symptoms.